Clinical Study Results
Research Sponsor: MedImmune, a wholly owned subsidiary of AstraZeneca
Drug Studied: Cotadutide
Study Purpose: This study was done to learn about the safety of cotadutide in participants with obesity and non-alcoholic fatty liver disease or non-alcoholic steatohepatitis
Protocol Number: D5671C00002
Thank you
Thank you for taking part in the clinical study for the study drug cotadutide, also called MEDI0382. You and all of the participants helped researchers learn more about cotadutide to help people with obesity and either:
- non-alcoholic fatty liver disease, also called NAFLD
- non-alcoholic steatohepatitis, also called NASH
MedImmune, a wholly owned subsidiary of AstraZeneca, sponsored this study and believes it is important to share the results of the study with you and the public. An independent non-profit organization called CISCRP helped prepare this summary of the study results for you. We hope it helps you understand and feel proud of your important role in medical research.
If you participated in the study and have questions about the results, please speak with the study doctor or staff at your study site.